Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title
04 Mar 2008 D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
03 Mar 2008 Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
03 Mar 2008 Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
29 Feb 2008 DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial in Patients With Major Depressive Disorder
29 Feb 2008 Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
29 Feb 2008 Takeda Submitted a New Drug Application for Ramelteon in Japan for Treatment of insomnia
29 Feb 2008 AstraZeneca Submits sNDA for Seroquel XR(TM) for the Treatment of Major Depressive Disorder
29 Feb 2008 U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
28 Feb 2008 Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
28 Feb 2008 XenoPort and GlaxoSmithKline report positive top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome
28 Feb 2008 Evotec Starts Phase II in Smoking Cessation with EVT 302
28 Feb 2008 FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
27 Feb 2008 NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
26 Feb 2008 Prana Announces Success in Phase IIa Clinical Trial of PBT2 in Early
26 Feb 2008 Allon's Phase II clinical trial shows statistically significant efficacy on human cognition and memory
25 Feb 2008 Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
25 Feb 2008 Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
21 Feb 2008 Forest and Cypress Announce FDA Acceptance for Review of New Drug Application for Milnacipran for the Treatment of Fibromyalgia
20 Feb 2008 Antisense Therapeutics Ltd Licenses ATL1102 to Teva Pharmaceutical Industries Ltd.
19 Feb 2008 Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
18 Feb 2008 Lundbeck further strengthens pipeline by moving Lu AA34893 into clinical phase II
14 Feb 2008 Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
12 Feb 2008 Valeant Pharmaceuticals reports positive Phase III results for retigabine in RESTORE 1
12 Feb 2008 Sosei Announces Start of AD 923 Phase III Studies in Europe
11 Feb 2008 AstraZeneca Submits Seroquel X(TM) in Europe for the Treatment of Bipolar Mania and Bipolar Depression and Seroquel(R) for Treatment of Bipolar Depression
11 Feb 2008 Cipher Provides CIP-TRAMADOL ER regulatory update
11 Feb 2008 Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG
08 Feb 2008 Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
07 Feb 2008 St. Jude Medical Announces Clinical Study of Deep Brain Stimulation for Depression
07 Feb 2008 Alnylam Reports Pre-clinical Progress with RNAi Therapeutics in Neurological Disease
06 Feb 2008 FDA Advisory Committee Supports Efficacy and Safety of Zyprexa® Long-Acting Injection (LAI) for Schizophrenia Treatment
05 Feb 2008 Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
05 Feb 2008 Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Tezampanel Demonstrates Compound is Safe and Well-Tolerated
05 Feb 2008 AVANIR Announces Progress on Zenvia(TM) Development
05 Feb 2008 Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
04 Feb 2008 BioLineRx Announces Positive Results from Phase 2a Trial of BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
04 Feb 2008 Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
04 Feb 2008 Penwest Announces Results of Phase IIa Clinical Study of Nalbuphine ER
01 Feb 2008 Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients
01 Feb 2008 MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
31 Jan 2008 FDA Accepts for Filing a Biologic License Application (BLA) for Dysport(R) in Cervical Dystonia
31 Jan 2008 Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia
30 Jan 2008 BTG plc Commences First Clinical Study of Novel Migraine Treatment
29 Jan 2008 Acorda Therapeutics Announces Successful Thorough QT Study of Fampridine-SR
29 Jan 2008 Pfizer Japan Receives Manufacturing and Marketing Authorization for Champix (R)
28 Jan 2008 Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
25 Jan 2008 Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
25 Jan 2008 Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
25 Jan 2008 Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
24 Jan 2008 Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 351 - 400 of 1619

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics